专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017075754A1 MOLD, MOLDING METHOD AND PRODUCT PRODUCED THROUGH MOLDING PROCESS 审中-公开
标题翻译：模具，成型方法和通过成型工艺生产的产品
公开(公告)号：WO2017075754A1
公开(公告)日：2017-05-11
申请号：PCT/CN2015/093645
申请日：2015-11-03
申请人： HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. , LIN, Chao-Hung , YEN, Wei-Feng , WEI, Guess , LEE, Te-Shun
发明人： LIN, Chao-Hung , YEN, Wei-Feng , WEI, Guess , LEE, Te-Shun
IPC分类号： B29C45/27
CPC分类号： B29C45/27 , A23G3/0031 , A23G3/0268 , B22C9/08 , B22D35/04 , B29C33/0061 , B29C39/24 , B29C39/40 , B29C45/0025 , B29C45/0046 , B29C45/0055 , B29C2045/0051 , B29C2045/0058 , B29C2045/0089 , C03B19/025
摘要： A mold (20) comprising: a molding component (21) including a cavity to form an object; and a supplementary component (22) including a bypass having a first opening (23) located at a first position of the molding component and a second opening (24) located at a second position of the molding component, wherein molten material flows from the first position to the second position via the molding component, and flows from the first opening to the second opening via the bypass, then fills into the second position of the molding component through the second opening.
摘要翻译：一种模具（20），包括：模制部件（21），其包括用于形成物体的空腔; 和包括旁路的辅助部件（22），所述旁路具有位于模制部件的第一位置处的第一开口（23）和位于模制部件的第二位置处的第二开口（24），其中熔融材料从第一位置经由模制部件定位到第二位置，并且经由旁路从第一开口流到第二开口，然后通过第二开口填充到模制部件的第二位置中。

2. 发明申请

WO2013019319A2 NON-REACTIVE BARRIER METAL FOR EUTECTIC BONDING PROCESS 审中-公开
标题翻译：用于保护性粘结工艺的非反应性阻挡金属
公开(公告)号：WO2013019319A2
公开(公告)日：2013-02-07
申请号：PCT/US2012/041783
申请日：2012-06-09
申请人： BRIDGELUX, INC. , LIN, Chao-kun
发明人： LIN, Chao-kun
CPC分类号： H01L33/62 , H01L24/29 , H01L24/32 , H01L24/48 , H01L24/73 , H01L33/0079 , H01L33/40 , H01L2224/2929 , H01L2224/29339 , H01L2224/32225 , H01L2224/48227 , H01L2224/73265 , H01L2924/00014 , H01L2924/01322 , H01L2924/10253 , H01L2924/12041 , H01L2924/12042 , H01L2924/181 , H01L2933/0066 , H01L2924/0655 , H01L2924/00012 , H01L2924/00 , H01L2224/45099 , H01L2224/45015 , H01L2924/207
摘要： A eutectic metal layer (e.g., gold/tin) bonds a carrier wafer structure to a device wafer structure. In one example, the device wafer structure includes a silicon substrate upon which an epitaxial LED structure is disposed. A layer of silver is disposed on the epitaxial LED structure. The carrier wafer structure includes a conductive silicon substrate covered with an adhesion layer. A layer of non-reactive barrier metal (e.g., titanium) is provided between the silver layer and the eutectic metal to prevent metal from the eutectic layer (e.g., tin) from diffusing into the silver during wafer bonding. During wafer bonding, the wafer structures are pressed together and maintained at more than 280°C for more than one minute. Use of the non- reactive barrier metal layer allows the total amount of expensive platinum used in the manufacture of a vertical blue LED manufactured on silicon to be reduced, thereby reducing LED manufacturing cost.
摘要翻译：共晶金属层（例如，金/锡）将载体晶片结构结合到器件晶片结构。在一个示例中，器件晶片结构包括其上设置有外延LED结构的硅衬底。一层银布置在外延LED结构上。载体晶片结构包括被粘合层覆盖的导电硅基板。在银层和共晶金属之间提供一层非反应性阻挡金属（例如钛），以防止晶片接合期间来自共晶层（例如锡）的金属扩散到银中。在晶片接合期间，将晶片结构压在一起并保持在280℃以上一分钟以上。使用非反应性阻挡金属层允许在制造在硅上制造的垂直蓝色LED中使用的昂贵铂的总量减少，从而降低LED制造成本。

3. 发明申请

WO2011011605A1 HYDROGEN PEROXIDE SENSORS BASED UPON PHOTO-INDUCED ELECTRON TRANSFER 审中-公开
标题翻译：过氧化氢传感器基于光电导电传输
公开(公告)号：WO2011011605A1
公开(公告)日：2011-01-27
申请号：PCT/US2010/042910
申请日：2010-07-22
申请人： OPTI MEDICAL SYSTEMS , HE, Huarui , LIN, Chao
发明人： HE, Huarui , LIN, Chao
IPC分类号： C07F15/00 , A61B5/00
CPC分类号： C07D221/14 , C07D401/12 , Y10T436/206664
摘要： The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q + is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q + . The invention also provides methods of detecting and determining the presence of analytes and/or hydrogen peroxide in a sample, as well as a substrate that comprises the compound of formula I.
摘要翻译：本发明提供式I F-L-Q（I）的化合物，其中F包括能够在激发波长处吸收能量的荧光团，并且在不存在猝灭剂的情况下发射不同于激发波长的发射波长的能量; Q包括猝灭剂; L包含具有两个末端的连接部分，一端与F共价结合，另一端与Q共价结合。化合物能够经历可逆反应（1），其如下：（1）其中Q +是氧化的形式Q表示不存在猝灭剂，Ox包含氧化剂，其能够将Q氧化成其氧化形式Q，并且Red包含还原剂，其能够将Q转化为其还原形式Q.化合物当能量照射时，当Q以其氧化态存在时，可以进行光诱导电子转移。本发明还提供了检测和确定样品中分析物和/或过氧化氢的存在以及包含式I化合物的底物的方法。

4. 发明申请

WO2010090857A2 METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS 审中-公开
标题翻译：扩增丙型肝炎病毒核酸的方法
公开(公告)号：WO2010090857A2
公开(公告)日：2010-08-12
申请号：PCT/US2010/021589
申请日：2010-01-21
申请人： VERTEX PHARMACEUTICALS INCORPORATED , KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
发明人： KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/707 , C12Q1/6883
摘要： A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
摘要翻译：扩增HCV感染样品中的HCV核酸的方法包括通过两阶段PCR扩增与来自样品的HCV RNA基因组互补的DNA模板片段，其中a 第一阶段PCR使用第一外部引物和第二外部引物，并且第二阶段PCR使用第一内部引物和第二内部引物。第一外部引物的核苷酸序列包含如SEQ ID NO：2所示的核苷酸序列; 或SEQ ID NO：9的核苷酸序列，其中任选地1,2或3个核苷酸是除SEQ ID NO：9的核苷酸以外的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO：3或4所示的核苷酸序列; 或如SEQ ID NO：10或11所示的核苷酸序列，其中任选地1,2或3个核苷酸是与SEQ ID NO：10和11的那些核苷酸不同的核苷酸。第一内部引物的核苷酸序列包含核苷酸序列如SEQ ID NO：5所示; 或SEQ ID NO：12，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：12的核苷酸。第二内部引物的核苷酸序列包含如SEQ ID NO：6或7所示的核苷酸序列 ; 或如SEQ ID NO：13或14所示的核苷酸序列，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：13和14的那些核苷酸。

5. 发明申请

WO2008073255A2 SPREADING LAYER AND HUMIDITY CONTROL LAYER FOR ENHANCING SENSOR PERFORMANCE 审中-公开
标题翻译：扩展层和湿度控制层，以提高传感器性能
公开(公告)号：WO2008073255A2
公开(公告)日：2008-06-19
申请号：PCT/US2007/024942
申请日：2007-12-06
申请人： OPTI MEDICAL SYSTEMS , RAMAMURTHY, Narayanan , HE, Huarui , LIN, Chao
发明人： RAMAMURTHY, Narayanan , HE, Huarui , LIN, Chao
IPC分类号： B01D69/14 , B01J20/28 , G01N33/18 , B01D69/10 , G01N33/52
CPC分类号： G01N33/525 , B01D2253/202 , B01D2257/80 , B01J20/28033 , B01J20/28097 , G01N21/274 , G01N21/6428 , G01N21/8483 , G01N2021/7786 , Y10T428/24273 , Y10T428/265 , Y10T428/31504
摘要： The invention is directed to optical sensors for measuring clinically relevant analytes, their methods of manufacture, and their various uses. In an effort to develop a dry calibration method for the optical sensors of the invention it is discovered that water content inside or in the immediate vicinity of a such a sensor can have a major impact on fluorescence intensity (i.e., a sensor's response in the dry state). Thus, one of the objectives of the invention is the elimination of the bias of sensor responses measured at different humidity environments.
摘要翻译：本发明涉及用于测量临床相关分析物，其制造方法及其各种用途的光学传感器。为了开发用于本发明的光学传感器的干式校准方法，发现这种传感器内部或附近的含水量可能对荧光强度具有主要影响（即传感器在干燥时的响应）州）。因此，本发明的目标之一是消除在不同湿度环境下测量的传感器响应的偏差。

6. 发明申请

WO2007131054A3 CHROMOIONOPHORE AND METHOD OF DETERMINING SODIUM IONS 审中-公开
公开(公告)号：WO2007131054A3
公开(公告)日：2007-11-15
申请号：PCT/US2007/068060
申请日：2007-05-02
申请人： OPTI MEDICAL SYSTEMS , HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
发明人： HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
IPC分类号： G01N21/75 , G01N23/00 , G01N21/00 , G01N21/62 , G01N21/76 , C09K3/00
摘要： The invention relates to methods of determining sodium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the sodium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

7. 发明申请

WO2007059221A9 HEPATITIS C VIRUS VARIANTS 审中-公开
标题翻译：丙型肝炎病毒变种
公开(公告)号：WO2007059221A9
公开(公告)日：2007-08-23
申请号：PCT/US2006044363
申请日：2006-11-13
申请人： VERTEX PHARMA , LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
发明人： LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
CPC分类号： C07K14/005 , C12N2770/24222 , C12Q1/34 , G01N33/56983 , G01N2500/00
摘要： The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
摘要翻译：本发明涉及HCV变体，特别是对诸如VX-950的蛋白酶抑制剂具有抗性的变体。还提供了与HCV变体有关的方法和组合物。进一步提供了从患者分离，鉴定和表征多种病毒变体的方法。

8. 发明申请

WO2007073326A1 SCREW 审中-公开
标题翻译：拧
公开(公告)号：WO2007073326A1
公开(公告)日：2007-06-28
申请号：PCT/SE2006/050557
申请日：2006-12-06
申请人： ESSVE PRODUKTER AB , LIN, Chao-Wei
发明人： LIN, Chao-Wei
IPC分类号： F16B25/10 , F16B25/08
CPC分类号： F16B25/103 , F16B25/0015 , F16B25/0052 , F16B25/0078
摘要： A screw comprising a head part (50), a pointed insert part (52) and a shank part disposed between said head part and said pointed insert part and having a shank axis (A). The shank part comprising a first shank segment (53) adjacent to said head part and having a first radius (r0) relative to the shank axis, and a second shank segment (54) adjacent to said pointed insert part and having a surface that is formed with a helical screw thread (55) including interconnected thread sections that have a second radius (ii) relative to the shank axis and larger than the first radius. The second shank segment is provided with one lengthwise groove (56) having a curvature so that the depth of said groove is larger than zero but smaller than the outer diameter of said threads, and the length of said groove is larger than zero but smaller than the whole length of said shank part, said lengthwise groove extends upward from the pointed end. The surface of the second shank segment being further formed with at least one projecting element (57) between two neighbouring interconnected ones of said thread sections, said projecting element having a greatest radial dimension (r2) with respect to the shank axis that is greater than the first radius (r0) and less than or equal the second radius (r1),
摘要翻译：一种螺钉，其包括头部（50），尖锐的插入部（52）和设置在所述头部和所述尖的插入部之间并具有柄轴线（A）的柄部。所述柄部分包括与所述头部部分相邻并且具有相对于所述柄轴线的第一半径（r0）的第一柄段（53）和与所述尖锐插入部件相邻的第二柄段（54），并且具有表面形成有螺旋螺纹（55），该螺旋螺纹（55）包括相对于柄轴线具有大于第一半径的第二半径（ii）的互连螺纹部分。第二柄段设置有一个具有曲率的纵向槽（56），使得所述槽的深度大于零但小于所述螺纹的外径，并且所述槽的长度大于零但小于所述柄部的整个长度，所述纵向凹槽从尖端向上延伸。所述第二柄段的表面进一步形成有在所述螺纹部分中的两个相邻的相互互连的所述螺纹部分之间的至少一个突出元件（57），所述突出元件相对于柄轴线具有最大的径向尺寸（r2）第一半径（r0）小于或等于第二半径（r1），

9. 发明申请

WO2007059221A3 HEPATITIS C VIRUS VARIANTS 审中-公开
公开(公告)号：WO2007059221A3
公开(公告)日：2007-05-24
申请号：PCT/US2006/044363
申请日：2006-11-13
申请人： VERTEX PHARMACEUTICALS, INC , LIN, Chao , KIEFFER, Tara , SARRAZIN, Christoph , KWONG, Ann
发明人： LIN, Chao , KIEFFER, Tara , SARRAZIN, Christoph , KWONG, Ann
IPC分类号： C07K14/18
摘要： The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

10. 发明申请

WO2006039488A3 HCV NS3-NS4A PROTEASE INHIBITION 审中-公开
公开(公告)号：WO2006039488A3
公开(公告)日：2007-02-22
申请号：PCT/US2005035191
申请日：2005-09-30
申请人： VERTEX PHARMA , LIN CHAO , TAYLOR WILLIAM P
发明人： LIN CHAO , TAYLOR WILLIAM P
IPC分类号： A61K38/00 , A61K31/42 , A61K31/425 , A61K31/4965
CPC分类号： A61K45/06 , A61K31/42 , A61K31/425 , A61K31/497 , A61K31/7056 , A61K38/07 , A61K38/21 , A61K2300/00
摘要： The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制非基因型1丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的活性。更具体地，本发明涉及抑制来自HCV基因型-2或HCV基因型-3的蛋白酶的活性。本发明的方法通过干扰HCV的生命周期而起作用的抑制剂，并且还可用作抗病毒剂。本发明还涉及包含这样的化合物的组合物，用于离体使用或给予患有基因型-2或基因型-3 HCV感染的患者。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式